Charles River Labs Intl Aktie
190,75 €
Deine Einschätzung
Charles River Labs Intl Aktie
Was spricht für und gegen Charles River Labs Intl in den nächsten Jahren?
Pro
Kontra
Rendite von Charles River Labs Intl im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Charles River Labs Intl | -0,96 % | -4,82 % | -12,06 % | 1,79 % | -10,45 % | -30,38 % | - |
Ironwood Pharmaceuticals | -0,86 % | 5,50 % | -24,34 % | -43,63 % | -43,63 % | -41,33 % | - |
Novocure Ltd | 8,08 % | 2,67 % | 59,96 % | -70,48 % | 53,63 % | -86,77 % | - |
Iovance Biotherapeutics Inc. | -4,71 % | -17,29 % | -39,46 % | -6,57 % | -1,72 % | -46,60 % | - |
Kommentare
News
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4th, at 10:00 a.m. CT
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks. Based on decades of
Charles River Laboratories Announces First-Quarter 2024 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03